Kestra Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Kestra Advisory Services’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.3K	Sell	12,078 -4,921	-29%	-$16.4K	﹤0.01%	3218
2026 Q1	$52.2K	Sell	16,999 -13,152	-44%	-$50.8K	﹤0.01%	3058
2025 Q4	$123K	Sell	30,151 -2,666	-8%	-$13.2K	﹤0.01%	3260
2025 Q3	$160K	Sell	32,817 -348	-1%	-$1.83K	﹤0.01%	2775
2025 Q2	$168K	Sell	33,165 -9,990	-23%	-$49.1K	﹤0.01%	2680
2025 Q1	$228K	Buy	43,155 +15,153	+54%	+$110K	﹤0.01%	2385
2024 Q4	$189K	Buy	+28,002	New	+$188K	﹤0.01%	2500

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kestra Advisory Services's RXRX Position: Q2 2026 in Review

Kestra Advisory Services reduced its Recursion Pharmaceuticals (RXRX) stake by 29% in Q2 2026, selling an estimated $16.4K and leaving 12,078 shares worth $44.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3218.

Kestra Advisory Services first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $228K in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Kestra Advisory Services held 12,078 shares of Recursion Pharmaceuticals worth $44.3K as of Q2 2026.
Kestra Advisory Services sold 4,921 Recursion Pharmaceuticals shares in Q2 2026, an estimated $16.4K.
Recursion Pharmaceuticals made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3218 holding.
Kestra Advisory Services first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Kestra Advisory Services's Recursion Pharmaceuticals position peaked at $228K in Q1 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.